Anika Therapeutics (NASDAQ:ANIK – Free Report) had its price target reduced by Barrington Research from $25.00 to $20.00 in a research note released on Thursday morning,Benzinga reports. Barrington Research currently has an outperform rating on the biotechnology company’s stock.
Anika Therapeutics Stock Performance
Shares of ANIK opened at $15.91 on Thursday. Anika Therapeutics has a 52-week low of $14.95 and a 52-week high of $29.11. The business’s fifty day moving average is $16.90 and its 200-day moving average is $19.51. The firm has a market cap of $233.02 million, a price-to-earnings ratio of -2.39 and a beta of 0.95.
Anika Therapeutics (NASDAQ:ANIK – Get Free Report) last issued its quarterly earnings results on Wednesday, March 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.13). Anika Therapeutics had a negative net margin of 59.40% and a negative return on equity of 2.22%. The business had revenue of $30.60 million during the quarter, compared to the consensus estimate of $29.00 million. As a group, research analysts forecast that Anika Therapeutics will post -0.84 EPS for the current fiscal year.
Institutional Investors Weigh In On Anika Therapeutics
About Anika Therapeutics
Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.
See Also
- Five stocks we like better than Anika Therapeutics
- How to Find Undervalued Stocks
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- How to Buy Cheap Stocks Step by Step
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Best Stocks Under $10.00
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.